NeurOp
NeurOp is a privately held, clinical-stage biopharmaceutical company based in Atlanta, Georgia. The company discovers and develops small-molecule, subunit-selective inhibitors of NMDA receptors (GluN2B-selective) with pH-dependent potency for central nervous system indications including subarachnoid hemorrhage (SAH), stroke, severe/neuropathic pain, and treatment-resistant depression. Its lead clinical candidate completed Phase 1 studies and has been advanced toward Phase 2 development.
Industries
Nr. of Employees
small (1-50)
Patents
GluN2B-subunit selective antagonists of the N-methyl-D-aspartate receptors with enhanced potency at acidic pH
US-12415790-B2
View Details
GluN2B-subunit selective antagonists of the N-methyl-D-aspartate receptors with enhanced potency at acidic pH
US-12415790-B2
View DetailsProducts
NP10679
A GluN2B-subunit-selective, pH-sensitive small-molecule NMDA receptor inhibitor developed for CNS disorders; reported to be orally bioavailable and suitable for IV administration with an approximately 17-hour half-life in humans.
NR2B selective antagonists
Preclinical pH-sensitive compounds developed by NeurOp for the relief of neuropathic pain by targeting NMDA receptors.
NP10679
A GluN2B-subunit-selective, pH-sensitive small-molecule NMDA receptor inhibitor developed for CNS disorders; reported to be orally bioavailable and suitable for IV administration with an approximately 17-hour half-life in humans.
NR2B selective antagonists
Preclinical pH-sensitive compounds developed by NeurOp for the relief of neuropathic pain by targeting NMDA receptors.
Services
Out-licensing and optioning of small-molecule GluN2B inhibitor portfolios to external developers and collaborators.
Out-licensing and optioning of small-molecule GluN2B inhibitor portfolios to external developers and collaborators.
Expertise Areas
- Small-molecule neuropharmacology
- Subunit-selective NMDA receptor modulation
- Context-dependent (pH-sensitive) drug design
- Preclinical efficacy and IND-enabling studies
Key Technologies
- Subunit-selective NMDA receptor modulation
- pH-dependent small-molecule inhibitors
- Medicinal chemistry and lead optimization
- Preclinical animal efficacy models (stroke, SAH, neuropathic pain)
News & Updates
Peer-reviewed clinical development article on a GluN2B-selective NMDA inhibitor for neurologic deficit after SAH.
Publication reporting Phase 1 clinical results for a pH-sensitive GluN2B-selective NMDA inhibitor.
Randomized SAD and MAD Phase 1 clinical studies completed with reported dose-linearity, ~17-hour half-life, and a benign safety profile supporting further development.
Investigational candidate received orphan drug designation from the U.S. FDA for treatment of subarachnoid hemorrhage.
Multi-year NIH funding supporting pre-IND and additional efficacy studies; includes a $3.5M award to support clinical testing and earlier multi-year awards for ischemia research.
Option agreement granted to another company for a portfolio of GluN2B negative allosteric modulators including a Phase 1-complete asset and preclinical compounds.
Peer-reviewed clinical development article on a GluN2B-selective NMDA inhibitor for neurologic deficit after SAH.
Publication reporting Phase 1 clinical results for a pH-sensitive GluN2B-selective NMDA inhibitor.
Randomized SAD and MAD Phase 1 clinical studies completed with reported dose-linearity, ~17-hour half-life, and a benign safety profile supporting further development.
Investigational candidate received orphan drug designation from the U.S. FDA for treatment of subarachnoid hemorrhage.
Multi-year NIH funding supporting pre-IND and additional efficacy studies; includes a $3.5M award to support clinical testing and earlier multi-year awards for ischemia research.
Option agreement granted to another company for a portfolio of GluN2B negative allosteric modulators including a Phase 1-complete asset and preclinical compounds.